Hypertension treatment at the crossroads: A role for economics?

American Journal of Hypertension

Volumn 26, Issue 11, 2013, Pages 1257-1259

  Arno, Peter S ^a,b   Viola, Deborah ^c  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; THIAZIDE DIURETIC AGENT; RENIN;

ANTIHYPERTENSIVE THERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; EDITORIAL; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; HYPERTENSION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; BLOOD; ECONOMICS; FEMALE; HEALTH CARE COST; MALE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ANTIHYPERTENSIVE AGENTS; FEMALE; HEALTH EXPENDITURES; HUMANS; HYPERTENSION; MALE; MODELS, ECONOMIC; RENIN;

EID: 84885678729     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt171     Document Type: Editorial

References (28)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics-2013 update a report from the American Heart Association. Circulation 2013; 127:e6-e245.
2. Olives C, Myerson R, Mokdad AH, Murray CJL, Lim SS. Prevalence, Awareness, Treatment, and Control of Hypertension in United States Counties, 2001-2009. PLoS ONE 2013; 8:e60308. doi:10.1371/journal.pone.0060308.
3. Valderrama AL, Gillespie C, King SC, George MG, Hong Y, Gregg E. Vital signs: Awareness and treatment of uncontrolled hypertension among adults: United States, 2003-2010. MMWR 2012; 61:1-7.
4. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 2011; 123:933-944.
5. Smith SM, Campbell JD. Cost-Effectiveness of Renin-Guided Treatment of Hpertensions. Am J Hypertens. 2013; doi:10.1093/ajh/ hpt099.
6. Wang G.Yan L.Ayala C.George MG.Fang J. Hypertension-associated expenditures for medications among U.S. adults Am J Hypertens 2013 doi:10.1093/ajh/hpt079.
7. Olson N, DeJong B, Hough A, Parra D. Plasma renin activity: Guided strategy for the management of hypertension. Pharmacotherapy 2012: 32:446-455.
8. Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH, Riehle JF, Walters CA, Lackland DT, Merali C, Sealey JE, Laragh JH. Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: A randomized controlled trial. Am J Hypertens 2009; 22:792-801.
9. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR. Plasma renin activity predicts blood pressure responses to b-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010; 23:1014-1022.
10. Gupta AK. Racial differences in response to antihypertensive therapy: does one size fits all? Int J Prev Med 2010; 1:217-219.
11. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom SM. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328:634-640.
12. Goldberger JJ, Buxton AE. Personalized medicine vs guideline-based medicine. JAMA 2013; 309:2559-2560.
13. Furberg CD. Renin-guided treatment of hypertension: time for action. Am J Hypertens 2010; 23:929-930.
14. Lenfant C. Clinical research to clinical practice: lost in translation? N Engl J Med 2003 349 868-874.
15. Stafford RS. Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002 J Am Coll Cardiol 2003 41 56-61.
16. Blumenthal D. Doctors and drug companies. N Engl J Med 2004; 351:1885-1890.
17. Wazan A. Physicians and the pharmaceutical industry: is a gift ever just a gift. JAMA 2000; 283:373-380.
18. Wang TJ, Ausiello JC, Stafford RS. Trends in antihypertensive drug advertising, 1985-1996. Circulation 1999; 99:2055-2057.
19. Ubel PA, Jepson C, Asch DA. Misperceptions about beta-blockers and diuretics: A national survey of primary care physicians. J Gen Intern Med 2003; 18:977-983.
20. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians- prescribing: A systematic review. PLoS Med 2010; 7:e1000352.
21. Major outcomes in high-risk hypertensive patients randomized to angiotensin- converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 23:2981-2997.
22. Morgan S, Bassett KL, Wright JM, Yan L. Firstline first? Trends in thiazide prescribing for hypertensive seniors. PLoS Med 2005; 2:e80.
23. Stafford R.S., Monti V. Furberg CD. Ma J. Longterm and short-term changes in antihypertensive prescribing by office-based physicians in the United States Hypertension 2006 48 213-218.
24. Davis D, O-Brien MA, Freemantle N, Wolf FM, Mazmanian P, Taylor-Vaisey A. Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA 1999; 282:867-874.
25. Tilbert JC, Wynia MK, Sheeler RD, Thorsteindottir B, James KM, Eggington JS, Liebow M, Hurst S, Danis M, Goold SD. Views of US physicians controlling health care costs. JAMA 2013; 410:380-388.
26. Chaix-Couturier C, Durand-Zaleski I, Jolly D, Durieux P. Effects of financial incentives on medical practice: Results from a systematic review of the literature and methodological issues. Int J Qual Health Care 2000; 12:133-142.
27. Hacker K. Walker DK. Achieving population health in accountable care organizations Am J Public Health 2013 103 163-1167.
28. Barr MS. The patient-centered medical home: Aligning payment to accelerate construction. Med Care Res Rev 2010; 67:492-499.